☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
dupixent
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma
October 13, 2020
Sanofi's Dupixent Receives the US FDA's Breakthrough Therapy Designation for Eosinophilic Esophagitis
September 14, 2020
Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma
September 8, 2020
Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis
August 19, 2020
Sanofi Reports the P-III (LIBERTY-CUPID Study C) Trial Data of Dupixent to Treat Chronic Spontaneous Urticaria (CSU)
September 11, 2024
Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)
July 3, 2024
Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)
May 31, 2024
Sanofi Highlights Data from the P-III (NOTUS) Study of Dupixent for COPD at ATS 2024 and Publishes in the NEJM
May 21, 2024
Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)
May 13, 2024
Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA for Dupixent with Priority Review to Treat COPD with Type 2 Inflammati...
February 23, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.